CN114456437A - 聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 - Google Patents
聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 Download PDFInfo
- Publication number
- CN114456437A CN114456437A CN202210091558.XA CN202210091558A CN114456437A CN 114456437 A CN114456437 A CN 114456437A CN 202210091558 A CN202210091558 A CN 202210091558A CN 114456437 A CN114456437 A CN 114456437A
- Authority
- CN
- China
- Prior art keywords
- polydopamine coating
- dressing
- solution
- modified
- codeposition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 66
- 239000004814 polyurethane Substances 0.000 title claims abstract description 66
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 63
- 229920001690 polydopamine Polymers 0.000 title claims abstract description 49
- 239000011248 coating agent Substances 0.000 title claims abstract description 45
- 238000000576 coating method Methods 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000243 solution Substances 0.000 claims abstract description 51
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000007983 Tris buffer Substances 0.000 claims abstract description 29
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 28
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims abstract description 19
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims abstract description 19
- 229940117986 sulfobetaine Drugs 0.000 claims abstract description 19
- 229960003638 dopamine Drugs 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 2
- 238000002635 electroconvulsive therapy Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 abstract description 6
- 238000012986 modification Methods 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 abstract description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- -1 betaine methacrylate ester Chemical class 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000000860 Compassion Fatigue Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/365—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2375/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2479/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2461/00 - C08J2477/00
- C08J2479/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用,所述制备方法包括如下步骤:将多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2和CuSO4依次添加到Tris溶液中,混合均匀后得到共沉积溶液;将海绵基材浸没于共沉积溶液中震荡处理,取出干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。本发明通过CuSO4/H2O2引发多巴胺和磺基甜菜碱甲基丙烯酸酯发生共沉积反应,并对聚氨酯海绵进行共沉积改性,使所制备的聚氨酯敷料表现出广谱、长效、稳定的抗菌性能。
Description
技术领域
本发明涉及医用材料技术领域,特别是一种聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用。
背景技术
目前,科技的发展使得人们对医用敷料的要求不断提高,传统敷料如纱布,棉花等容易滋生细菌,创面渗出液易与干燥真皮组织一起形成痂皮,妨碍上皮化,同时创面易与敷料粘连,换药揭开时会对患者带来二次创伤,因此发明一种新型伤口敷料至关重要。
临床上使用的敷料种类有很多其中,泡沫型聚氨酯医用敷料适用于创面肉芽形成期,泡沫型敷料能吸收多余的创面渗出液,同时能够阻隔外界异物和部分细菌,保护暴露的神经末梢,减轻疼痛。同时泡沫敷料由于保持湿润,从而避免了创面渗出物的过度蒸发而形成干痂,因此在更换敷料时不会产生再次性机械性损伤,有利于创面的愈合。伤口的细菌种类比较多,常见致病菌有葡萄球菌、链球菌、大肠杆菌等,其特点是:同一种致病菌可以引起几种不同的化脓性感染,如金黄色葡萄球菌能引起疖、痈、脓肿、伤口感染等,而不同的致病菌又可引起同一种疾病,如金黄色葡萄球菌、链球菌和大肠杆菌都能引起急性蜂窝织炎软组织脓肿伤口感染等,这些都会表现出有化脓性炎症的共同牲特征,即红、肿、热、痛和功能障碍,防治上也有共同性。现有的抗菌敷料主要通过抗菌剂与原料共混产生,虽然具有抗菌的效果,但大部分却无法实现长效抑菌,且抗菌的范围窄,效果差。故需要提出一种新的抗菌敷料用于解决现有技术中所存在的上述问题。
发明内容
本发明的目的在于,提供一种聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用,用于解决现有抗菌敷料存在抑菌时效短、抗菌范围窄、效果差的问题。
为解决上述技术问题,本发明所提供的第一解决方案为:一种聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,包括如下步骤:将多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2和CuSO4依次添加到Tris溶液中,混合均匀后得到共沉积溶液;将海绵基材浸没于共沉积溶液中震荡处理,取出干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
优选的,Tris溶液中Tris的质量分数为0.5~0.8%,且Tris、多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2、CuSO4的质量比为6:(1~10):(5~50):(1~5):(0.1~3)。
更优选的,Tris溶液中Tris的质量分数为0.6%。
优选的,海绵基材为未改性的聚氨酯海绵。
优选的,震荡处理的具体步骤为:在空气振荡器中,对浸没于共沉积溶液的海绵基材进行震荡,震荡时间为5~9天。
优选的,干燥的温度为50~60℃。
为解决上述技术问题,本发明所提供的第二解决方案为:一种聚多巴胺涂层改性的抗菌聚氨酯敷料,该聚多巴胺涂层改性的抗菌聚氨酯敷料由前述第一解决方案中的聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法制得。该聚多巴胺涂层改性的抗菌聚氨酯敷料作为医用敷料进行应用。
本发明的有益效果是:区别于现有技术的情况,本发明提供一种聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用,通过CuSO4/H2O2引发多巴胺和磺基甜菜碱甲基丙烯酸酯发生共沉积反应,并对聚氨酯海绵进行共沉积改性,使所制备的聚氨酯敷料表现出广谱、长效、稳定的抗菌性能。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,均属于本发明保护的范围。
对于本发明所提供的第一解决方案,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法包括如下步骤:
(1)将多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2和CuSO4依次添加到Tris溶液中,混合均匀后得到共沉积溶液。本步骤中,Tris溶液中Tris的质量分数为0.5~0.8%,进一步优选的,Tris溶液中Tris的质量分数为0.6%;Tris、多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2、CuSO4的质量比为6:(1~10):(5~50):(1~5):(0.1~3)。
(2)将海绵基材浸没于共沉积溶液中震荡处理,取出干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。本步骤中,海绵基材为未改性的聚氨酯海绵,将海绵基材浸没于共沉积溶液,在空气振荡器中进行震荡,震荡时间为5~9天,对海绵基材进行充分改性;震荡完成后,在50~60℃的烘箱中干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
对于本发明所提供的第二解决方案,该聚多巴胺涂层改性的抗菌聚氨酯敷料由前述第一解决方案中的聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法制得,则两个解决方案中的聚多巴胺涂层改性的抗菌聚氨酯敷料在物化性质上保持一致;该聚多巴胺涂层改性的抗菌聚氨酯敷料作为医用敷料进行应用。
进一步地,对本发明中的聚多巴胺涂层改性的抗菌聚氨酯敷料的机理和优势进行详细阐述:
1)本发明通过CuSO4/H2O2引发多巴胺和磺基甜菜碱甲基丙烯酸酯发生共沉积反应,生成聚多巴胺(简称PDA)和聚磺基甜菜碱甲基丙烯酸酯(简称PSBMA),并对聚氨酯海绵进行共沉积改性。其中,适量浓度的铜离子既能促进多巴胺和磺基甜菜碱甲基丙烯酸酯的聚合,又提供了良好的抗菌性;而反应生成的聚磺基甜菜碱甲基丙烯酸酯具有带正电荷和带负电荷的部分,可以通过静电诱导的水合作用强力结合水分子,对非特异性蛋白质吸附表现出很高的抵抗力,可以有效地避免细菌粘附,从而防止细菌形成的生物膜,表现出较强的抗菌性能;由于生成的聚多巴胺和聚磺基甜菜碱甲基丙烯酸酯具有很好的沉积作用,从而使得改性的聚氨酯表面具有长效稳定的抗菌性能。
2)不同于传统的共混,本发明采用共沉积的方法对聚氨酯海绵进行抗菌改性,是一种新型的抗菌改性方法,并且共沉积溶液可以反复多次使用,显著提高了原料的利用率。
下面通过具体实施例对本发明中的聚多巴胺涂层改性的抗菌聚氨酯敷料进行试验分析。
实施例1
本实施例中,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备步骤如下:
(1)取3g的Tris加500ml水配制Tris溶液,再依次加入0.5g多巴胺,3g磺基甜菜碱甲基丙烯酸酯,0.5mlH2O2和0.3gCuSO4,混合均匀后得到共沉积溶液。
(2)取一块5cm*5cm*0.5cm的普通聚氨酯海绵,置于共沉积溶液中,在空气振荡器中震荡5天,取出,烘箱50℃干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
实施例2
本实施例中,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备步骤如下:
(1)取3g的Tris加500ml水配制Tris溶液,再依次加入2g多巴胺,25g磺基甜菜碱甲基丙烯酸酯,0.5ml H2O2和1.5g CuSO4,混合均匀后得到共沉积溶液。
(2)取一块5cm*5cm*0.5cm的普通聚氨酯海绵,置于共沉积溶液中,在空气振荡器中震荡5天,取出,烘箱50℃干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
实施例3
本实施例中,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备步骤如下:
(1)取3g的Tris加500ml水配制Tris溶液,再依次加入0.5g多巴胺,25g磺基甜菜碱甲基丙烯酸酯,1ml H2O2和1g CuSO4,混合均匀后得到共沉积溶液。
(2)取一块5cm*5cm*0.5cm的普通聚氨酯海绵,置于共沉积溶液中,在空气振荡器中震荡5天,取出,烘箱50℃干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
实施例4
本实施例中,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备步骤如下:
(1)取3g的Tris加500ml水配制Tris溶液,再依次加入1g多巴胺,15g磺基甜菜碱甲基丙烯酸酯,1ml H2O2和0.6g CuSO4,混合均匀后得到共沉积溶液。
(2)取一块5cm*5cm*0.5cm的普通聚氨酯海绵,置于共沉积溶液中,在空气振荡器中震荡5天,取出,烘箱50℃干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
实施例5
本实施例中,聚多巴胺涂层改性的抗菌聚氨酯敷料的制备步骤如下:
(1)取3g的Tris加500ml水配制Tris溶液,再依次加入1g多巴胺,15g磺基甜菜碱甲基丙烯酸酯,1ml H2O2和0.625g CuSO4,混合均匀后得到共沉积溶液。
(2)取一块5cm*5cm*0.5cm的普通聚氨酯海绵,置于共沉积溶液中,在空气振荡器中震荡10天,取出,烘箱50℃干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
对比例1
本对比例中,选用的未经改性的普通市售聚氨酯海绵敷料(赛福康瑞)。
测试1细胞毒性测试
对上述实施例1~5中所制备的聚多巴胺涂层改性的抗菌聚氨酯敷料进行细胞毒性测试,具体测试步骤如下:首先,提取样品浸出液,将灭菌后的样品浸入1mL的DMEM培养基中,在37℃下保持24h;然后使用无菌过滤器(孔径:0.22μm),通过过滤对培养基进行灭菌;随后,将成纤维细胞接种到96孔板的每个孔中,并在37℃下孵育24小时;然后用500μL浸出液或含有10%胎牛血清的原始培养基替换培养基;24小时后,将培养基更换为含有10μLCCK8溶液的100μL原始培养基,然后在37℃下孵育2小时;最后,使用酶标仪测定波长450nm处的OD值,并计算细胞存活率。所测试结果如表1所示,可以看出,在实施例1~5所制备敷料作用下细胞存活率保持在85%以上,证明能够作为医用敷料进行应用。
表1细胞毒性测试
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | |
细胞存活率/% | 86% | 89% | 92% | 91% | 89% |
测试2抗菌性能测试
对上述实施例1~5中所制备的聚多巴胺涂层改性的抗菌聚氨酯敷料进行抗菌测试,抗菌试验采用革兰氏阴性菌(大肠杆菌)和革兰氏阳性菌(金黄色葡萄球菌)评估膜抗菌性能的模型生物污垢,测试步骤如下:首先,将膜样品(1cm×1cm)放入培养皿中,用紫外光消毒30分钟;然后,在膜表面加入300微升细胞浓度为2×106CFU/毫升的细菌溶液,并在37℃孵育24小时。孵育后,将细菌从膜表面移除并转移到50毫升PBS溶液中(pH=7.4);然后,将细菌溶液铺在琼脂平板上,并在37℃下再培养24小时;最后,计数细菌菌落,并计算抗菌率。测试过程中,分别记录并计算经过24h、48h和72h时的对菌株的抑菌率,结果如表2所示,可以看出,在实施例1~5所制备敷料作用下,即使经过了72h后,所制备敷料对测试菌株的抑菌率仍能够维持在80%以上,而对比例1的抑菌率降低明显且远低于实施例1~5的抑菌水平,则证明所制备敷料具有长效稳定的抗菌能力。
表2抗菌性能测试
区别于现有技术的情况,本发明提供一种聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用,通过CuSO4/H2O2引发多巴胺和磺基甜菜碱甲基丙烯酸酯发生共沉积反应,并对聚氨酯海绵进行共沉积改性,使所制备的聚氨酯敷料表现出广谱、长效、稳定的抗菌性能。
需要说明的是,以上各实施例均属于同一发明构思,各实施例的描述各有侧重,在个别实施例中描述未详尽之处,可参考其他实施例中的描述。
以上所述实施例仅表达了本发明的实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (8)
1.一种聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,包括如下步骤:
将多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2和CuSO4依次添加到Tris溶液中,混合均匀后得到共沉积溶液;
将海绵基材浸没于所述共沉积溶液中震荡处理,取出干燥至恒重,得到聚多巴胺涂层改性的抗菌聚氨酯敷料。
2.根据权利要求1中所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,所述Tris溶液中Tris的质量分数为0.5~0.8%,且所述Tris、多巴胺、磺基甜菜碱甲基丙烯酸酯、H2O2、CuSO4的质量比为6:(1~10):(5~50):(1~5):(0.1~3)。
3.根据权利要求2中所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,所述Tris溶液中Tris的质量分数为0.6%。
4.根据权利要求1中所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,所述海绵基材为未改性的聚氨酯海绵。
5.根据权利要求1中所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,所述震荡处理的具体步骤为:在空气振荡器中,对浸没于所述共沉积溶液的所述海绵基材进行震荡,震荡时间为5~9天。
6.根据权利要求1中所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法,其特征在于,所述干燥的温度为50~60℃。
7.一种聚多巴胺涂层改性的抗菌聚氨酯敷料,其特征在于,所述聚多巴胺涂层改性的抗菌聚氨酯敷料由权利要求1~7中任一所述聚多巴胺涂层改性的抗菌聚氨酯敷料的制备方法制得。
8.如权利要求7中所述聚多巴胺涂层改性的抗菌聚氨酯敷料作为医用敷料的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210091558.XA CN114456437A (zh) | 2022-01-26 | 2022-01-26 | 聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210091558.XA CN114456437A (zh) | 2022-01-26 | 2022-01-26 | 聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114456437A true CN114456437A (zh) | 2022-05-10 |
Family
ID=81412135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210091558.XA Pending CN114456437A (zh) | 2022-01-26 | 2022-01-26 | 聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114456437A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104194023A (zh) * | 2014-08-12 | 2014-12-10 | 东南大学 | 一种基于多巴胺提高医用聚氨酯材料表面亲水性和生物相容性的方法 |
CN107987578A (zh) * | 2017-12-08 | 2018-05-04 | 山东交通学院 | 一种具有防污杀菌功能的表面涂层产品的制备方法 |
CN109912826A (zh) * | 2019-03-25 | 2019-06-21 | 中国科学院兰州化学物理研究所 | 一种表面修饰有亲水润滑涂层的生物材料及其制备方法 |
CN112717207A (zh) * | 2020-12-15 | 2021-04-30 | 山东大学 | 一种基于仿生多巴胺的长效抗菌多功能涂层及其制备方法和应用 |
-
2022
- 2022-01-26 CN CN202210091558.XA patent/CN114456437A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104194023A (zh) * | 2014-08-12 | 2014-12-10 | 东南大学 | 一种基于多巴胺提高医用聚氨酯材料表面亲水性和生物相容性的方法 |
CN107987578A (zh) * | 2017-12-08 | 2018-05-04 | 山东交通学院 | 一种具有防污杀菌功能的表面涂层产品的制备方法 |
CN109912826A (zh) * | 2019-03-25 | 2019-06-21 | 中国科学院兰州化学物理研究所 | 一种表面修饰有亲水润滑涂层的生物材料及其制备方法 |
CN112717207A (zh) * | 2020-12-15 | 2021-04-30 | 山东大学 | 一种基于仿生多巴胺的长效抗菌多功能涂层及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10695457B2 (en) | Antiseptic wound dressing | |
Wiegand et al. | Antimicrobial functionalization of bacterial nanocellulose by loading with polihexanide and povidone-iodine | |
Lu et al. | A novel in situ‐formed hydrogel wound dressing by the photocross‐linking of a chitosan derivative | |
CN109432484B (zh) | 一种医用超疏水抗菌敷料及其制备方法 | |
CN109369948B (zh) | 一种细菌纤维素/聚乙烯醇抗菌水凝胶及其制备方法和应用 | |
CN105797193B (zh) | 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 | |
Liu et al. | Template-assisted magnetron sputtering of cotton nonwovens for wound healing application | |
WO2023231050A1 (zh) | 一种强韧抗菌水凝胶敷料及其制备方法 | |
CN106110383A (zh) | 一种壳聚糖藻酸盐敷料及其冻干制备方法 | |
CN113265021A (zh) | 一种铁基纳米酶水凝胶的制备方法及应用 | |
Ramasamy et al. | Fabrication of collagen with polyhexamethylene biguanide: A potential scaffold for infected wounds | |
CN112494713A (zh) | 一种益生菌结合氧化白及多糖-壳聚糖复合水凝胶及其制备方法和用途 | |
US20160235881A1 (en) | Non-adherent hydrogel coating for wound dressings and methods for making the same | |
Zhou et al. | Metal-phenolic self-assembly shielded probiotics in hydrogel reinforced wound healing with antibiotic treatment | |
Yang et al. | A sandwich structure composite wound dressing with firmly anchored silver nanoparticles for severe burn wound healing in a porcine model | |
CN107441546B (zh) | 一种含银抗菌敷料的制备方法 | |
CN112870431B (zh) | 具有g-四链体结构用作级联反应器的抗菌水凝胶及其制备方法及应用 | |
CN110917391A (zh) | 一种多肽修饰海藻酸钠/pva水凝胶敷料及其制备方法 | |
CN113384741B (zh) | 一种具有主动与被动双重抗菌机理的季铵盐聚膦腈水凝胶伤口敷料及制备方法 | |
CN114456437A (zh) | 聚多巴胺涂层改性的抗菌聚氨酯敷料及其制备方法和应用 | |
CN113663122A (zh) | 一种抗炎、抗菌、抗肿瘤的多功能水凝胶材料及其制备方法和应用 | |
CN108434507B (zh) | 离子介导敷料及其制备方法和应用 | |
CN111714693A (zh) | 一种纤维素抗菌膜及其制备方法 | |
CN114146214A (zh) | 一种含抗菌肽的水凝胶及其制备方法和应用 | |
CN110507846B (zh) | 一种长效抗菌促愈合角蛋白敷料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230329 Address after: 572024 Building 9, UFIDA Industrial Park, yazhouwan science and Technology City, Yazhou District, Sanya City, Hainan Province Applicant after: Sanya science and Education Innovation Park Wuhan University of Technology Address before: 430070 Hubei Province, Wuhan city Hongshan District Luoshi Road No. 122 Applicant before: WUHAN University OF TECHNOLOGY |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220510 |
|
RJ01 | Rejection of invention patent application after publication |